PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, cilt.138, ss.142-147, 2015 (SCI-Expanded)
Introduction: Patients with schizophrenia have cognitive dysfunctions: positive psychotic symptoms are the primary purposes for schizophrenia treatment Improvements in cognitive function should be a characteristic of all newly developed drugs for the treatment of schizophrenia with dementia. Thus, we investigated the effects of the second-generation antipsychotic ziprasidone, dopamine D1 antagonist SCH-23390 and dopamine D3 antagonist SB-277011 on spatial learning and memory.